Hydrocortisone Considerably Reduces Seroma Risk After Breast Cancer Surgery, Major Review Finds
Table of Contents
A new systematic review and meta-analysis published in Annals of Saudi Medicine in July 2025 reveals that perioperative corticosteroid use dramatically lowers the risk of seroma formation following breast cancer surgery, with hydrocortisone demonstrating the most significant benefit.
Seroma, a collection of fluid at the surgical site, is a common and often debilitating complication for patients undergoing mastectomy and lumpectomy, affecting up to 85% of cases. It can lead to discomfort, increased risk of infection, delayed healing, and negatively impact cosmetic results. This new research offers a possibly simple and effective preventative strategy.
Corticosteroids Cut Seroma Risk by Nearly 70%
The thorough analysis, encompassing data from seven randomized controlled trials and 689 patients, showed that corticosteroids reduced seroma risk by nearly 70% (Odds Ratio: 0.31; 95% Confidence Interval: 0.20-0.48). this finding underscores the potential of these readily available medications to improve patient outcomes.
“The pooled analysis demonstrated that corticosteroids lowered seroma risk by nearly 70%,” a senior researcher stated.
Pro tip:– Hydrocortisone, a corticosteroid, significantly reduces seroma risk after breast cancer surgery. the review found it more effective than methylprednisolone.This could become a standard preventative measure.
Hydrocortisone Outperforms Other Steroids
While all corticosteroids examined showed a positive effect, hydrocortisone emerged as the clear leader.It produced a significantly greater reduction in seroma formation compared to methylprednisolone (Hydrocortisone OR: 0.14 vs. Methylprednisolone OR: 0.41; P=.0155). Researchers believe this superior efficacy is likely due to hydrocortisone’s potent anti-inflammatory properties and its ability to reduce vascular permeability and subsequent fluid accumulation at the surgical site.
reader question:– What is seroma? it is a fluid collection at the surgical site, common after breast cancer surgery. It can cause discomfort, infection risk, and delayed healing. This study suggests a preventative measure.
Publication Bias Addressed, Findings Remain Robust
the study authors acknowledged a moderate degree of publication bias, identifying three potentially missing studies through the Duval and Tweedie method. However, even after adjusting for these potential omissions, the positive effect of corticosteroids remained statistically significant (adjusted OR: 0.42; 95% CI: 0.28-0.63, P<.001).Furthermore, low study heterogeneity (I=17.3%) suggests consistent results across the included trials.
Clinical Implications and Future Research
The findings have significant clinical implications for breast cancer surgery. The research suggests that administering corticosteroids around the time of surgery – a perioperative approach – could become a standard preventative measure. Though, the authors caution that further research is needed to determine optimal dosing strategies and management timing.
Subgroup analyses indicated that the timing and route of corticosteroid administration may influence effectiveness, though the overall benefit remained consistent. Larger, more rigorously designed randomized trials are warranted to refine these protocols.
Careful patient selection and shared decision-making will be crucial, as clinicians weigh the potential benefits of corticosteroids against individual patient factors and existing institutional guidelines. This approach ensures personalized care and maximizes positive outcomes for those undergoing breast cancer surgery.
